)
)
Insmed Investor Relations Material
Latest events
Q3 2024
Insmed
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Insmed Incorporated
Access all reports
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.
Key slides for Insmed Incorporated
Q4 2023
Insmed Incorporated
Jefferies London Healthcare Conference 2024
Insmed Incorporated
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
INSM
Country
🇺🇸 United States